Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo

Journal of Pathology

Volumn 222, Issue 2, 2010, Pages 148-157

  Ngô, Charlotte ^a   Nicco, Carole ^a   Leconte, Mahaut ^a   Chéreau, Christiane ^a   Arkwright, Sylviane ^a   Vacher Lavenu, Marie Cécile ^a   Weill, Bernard ^a   Chapron, Charles ^a   Batteux, Frédéric ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Endometriosis; ERK pathway; Leflunomide; Mouse model; Protein kinase inhibitors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; LEFLUNOMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN KINASE INHIBITOR; TERIFLUNOMIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LYSATE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ENDOMETRIOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; EX VIVO STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STROMA CELL; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG SCREENING; ENDOMETRIUM; ENZYMOLOGY; METHODOLOGY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSPLANTATION;

ADULT; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; STROMAL CELLS;

EID: 77957968871     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2756     Document Type: Article

References (46)

1. Bulun SE. Endometriosis. N Engl J Med 2009;360:268-279.
2. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-1799.
3. Swiersz LM. Role of endometriosis in cancer and tumor development. Ann N Y Acad Sci 2002;955:281-292; discussion 293-285, 396-406.
4. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307-1318.
5. Chapron C, Fauconnier A, Dubuisson JB, et al. Deep infiltrating endometriosis: relation between severity of dysmenorrhoea and extent of disease. Hum Reprod 2003;18:760-766.
6. Jacobson TZ, Duffy JM, Barlow D, et al. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2009; CD001300.
7. ASRM: the Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. Fertil Steril 2006;85:1307-1318.
8. Ngo C, Nicco C, Leconte M, et al. Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo. Fertil Steril 2009; [Epub ahead of print].
9. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912.
10. Raman M, Cobb MH. MAP kinase modules: many roads home. Curr Biol 2003;13: R886-R888.
11. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-183.
12. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004;117:4619-4628.
13. Yoshida S, Harada T, Iwabe T, et al. A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis. Hum Reprod 2004;19:1821-1825.
14. Tamura M, Sebastian S, Yang S, et al. Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2. J Clin Endocrinol Metab 2002;87:3263-3273.
15. Ozaki T, Takahashi K, Kanasaki H, et al. Expression and activation of mitogen-activated protein kinase in the human endometrium during the menstrual cycle. Am J Obstet Gynecol 2006;195:1343-1350.
16. Murk W, Atabekoglu CS, Cakmak H, et al. ERK activity in the human endometrium: possible roles in the pathogenesis of endometriosis. J Clin Endocrinol Metab 2008;93:3532-3540.
17. Gentilini D, Busacca M, Di Francesco S, et al. PI3K/Akt and ERK1/2 signalling pathways are involved in endometrial cell migration induced by 17beta-estradiol and growth factors. Mol Hum Reprod 2007;13:317-322.
18. Ngo C, Chereau C, Nicco C, et al. Reactive oxygen species controls endometriosis progression. Am J Pathol 2009;175:225-234.
19. McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 2006;8:1775-1789.
20. Hornung D, Ryan IP, Chao VA, et al. Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J Clin Endocrinol Metab 1997;82:1621-1628.
21. Grange PA, Chereau C, Raingeaud J, et al. Production of superoxide anions by keratinocytes initiates P. acnes-induced inflammation of the skin. PLoS Pathog 2009; i5: e1000527.
22. Laurent A, Nicco C, Chereau C, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005;65:948-956.
23. Lugli A, Zlobec I, Minoo P, et al. Role of the mitogenactivated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signalregulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach. Hum Pathol 2006;37:1022-1031.
24. Bruner-Tran KL, Webster-Clair D, Osteen KG. Experimental endometriosis: the nude mouse as a xenographic host. Ann N Y Acad Sci 2002;955:328-339; discussion 340-322, 396-406.
25. Yoshino O, Osuga Y, Hirota Y, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol 2004;52:306-311.
26. OuYang Z, Hirota Y, Osuga Y, et al. Interleukin-4 stimulates proliferation of endometriotic stromal cells. Am J Pathol 2008;173:463-469.
27. Hirata T, Osuga Y, Hamasaki K, et al. Interleukin (IL)-17A stimulates IL-8 secretion, cyclooxygensase-2 expression, and cell proliferation of endometriotic stromal cells. Endocrinology 2008;149:1260-1267.
28. Yoshino O, Osuga Y, Koga K, et al. FR 167653, a p38 mitogenactivated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol 2006;72:85-93.
29. Ulukus M, Cakmak H, Arici A. The role of endometrium in endometriosis. J Soc Gynecol Invest 2006;13:467-476.
30. Matsuzaki S, Canis M, Vaurs-Barriere C, et al. DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection. Fertil Steril 2005;84(Suppl 2):1180-1190.
31. Wu Y, Strawn E, Basir Z, et al. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics 2006;1:106-111.
32. Aghajanova L, Horcajadas JA, Weeks JL, et al. The protein kinase A pathway-regulated transcriptome of endometrial stromal fibroblasts reveals compromised differentiation and persistent proliferative potential in endometriosis. Endocrinology 2010;151:1341-1355.
33. Kanda S, Kanetake H, Miyata Y. Long-term exposure of human renal carcinoma cells to PD98059 induces epithelial-mesenchymal transition-like phenotype and enhanced motility. Mol Cell Biochem 2008;309:69-76.
34. Rambal AA, Panaguiton ZL, Kramer L, et al. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia 2009;23:1744-1754.
35. Meira DD, de Almeida VH, Mororo JS, et al. Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer 2009;101:782-791.
36. Sharma A, Tran MA, Liang S, et al. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 2006;66:8200-8209.
37. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41:421-430.
38. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-849.
39. Aytan H, Caglar P, Uygur D, et al. Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. Fertil Steril 2007;87:698-701.
40. Kalden JR, Schattenkirchner M, Sorensen H, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up study. Arthritis Rheum 2003;48:1513-1520.
41. Maddison P, Kiely P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 2005;44:280-286.
42. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-134.
43. Al-Jefout M, Dezarnaulds G, Cooper M, et al. Diagnosis of endometriosis by detection of nerve fibres in an endometrial biopsy: a double blind study. Hum Reprod 2009;24:3019-3024.
44. Al-Jefout M, Andreadis N, Tokushige N, et al. A pilot study to evaluate the relative efficacy of endometrial biopsy and full curettage in making a diagnosis of endometriosis by the detection of endometrial nerve fibers. Am J Obstet Gynecol 2007;197:578e1-4.
45. Bokor A, Kyama CM, Vercruysse L, et al. Density of small diameter sensory nerve fibres in endometrium: a semi-invasive diagnostic test for minimal to mild endometriosis. Hum Reprod 2009;24:3025-3032.
46. Wang G, Tokushige N, Russell P, et al. Neuroendocrine cells in eutopic endometrium of women with endometriosis. Hum Reprod 2010;25:387-391.